Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.48 |
| ▸ | GRM5 | P41594 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1476807 | 0.85 | CYP11B1 (0.44) | CHRNB2CHRNA4CYP11B1CYP11B2GRM5 | |
| SCHEMBL1476905 | 0.81 | CYP11B1 (0.51) | CHRNB2CHRNA4CYP11B1CYP11B2 | |
| SCHEMBL1476892 | 0.81 | PTGDR2 (0.44) | CHRNB2CHRNA4CYP11B1CYP11B2GRM5 | |
| SCHEMBL1476932 | 0.81 | RAF1 (0.49) | CHRNB2CHRNA4CYP11B1CYP11B2GRM5 | |
| SCHEMBL1477360 | 0.79 | GRM5 (0.55) | CHRNB2CHRNA4GRM5 | |
| SCHEMBL1476752 | 0.77 | HPGDS (0.47) | CHRNB2CHRNA4GRM5 | |
| SCHEMBL1477267 | 0.77 | CYP11B1 (0.46) | CHRNB2CHRNA4CYP11B1CYP11B2GRM5 | |
| SCHEMBL1476558 | 0.76 | CHRNB2 (0.51) | CHRNB2CHRNA4CYP11B1CYP11B2GRM5 | |
| SCHEMBL1477481 | 0.76 | CYP11B1 (0.45) | CHRNB2CHRNA4CYP11B1CYP11B2GRM5 | |
| SCHEMBL1476533 | 0.75 | GRM5 (0.53) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915424-B2 | Analgesics; anxiolytic agents | ELI LILLY AND COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1729771-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-14 | — | — | EP | disclosed |
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | ELI LILLY AND COMPANY (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1729771-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094822-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194647-A1 | Pyridyl Derivatives and Their Use as Mglu5 Antagonists | HRH4, CNR2, CNR1 | CHRNB2 57/4885CHRNA4 6/4885CYP11B1 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.